Should cd4 levels be monitored in a patient on temozolomide?

Sriram Gonakoti, Luis Parra-Rodriguez

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Temozolomide is an alkylating agent, indicated in the treatment of refractory anaplastic astrocytoma and newly diagnosed glioblastoma. We describe a case of Salmonella typhimurium bacteraemia associated with septic arthritis in the setting of concurrent temozolomide use. Case: A 67-year-old woman presented with acute onset of bilateral knee pain and swelling. She had a medical history of glioblastoma multiforme treated with temozolomide. Synovial fluid analysis and blood cultures revealed S. typhimurium, confirming a diagnosis of S. typhimurium bacteraemia associated with septic arthritis. Conclusion: We conclude that chemotherapy with temozolomide and corticosteroid use will increase an individual's susceptibility to a wide variety of opportunistic infections akin to HIV-associated acquired immunodeficiency syndrome (AIDS). Furthermore, we hypothesize a possible benefit of monitoring CD4 levels and prophylaxis against opportunistic infections (based on the CD4 levels) in individuals receiving temozolomide-based chemotherapy, similar to HIV-AIDS.

Original languageEnglish
JournalEuropean Journal of Case Reports in Internal Medicine
Volume8
Issue number3
DOIs
StatePublished - 2021

Keywords

  • Non-typhoidal salmonellae
  • Septic arthritis
  • Temozolomide

Fingerprint

Dive into the research topics of 'Should cd4 levels be monitored in a patient on temozolomide?'. Together they form a unique fingerprint.

Cite this